Actively Recruiting
Talk-to-Jo Intelligent Digital Health Companion for Neurocognitive Disorders and Caregivers: A Qualitative Study
Led by Olivier Beauchet · Updated on 2025-02-12
40
Participants Needed
1
Research Sites
34 weeks
Total Duration
On this page
Sponsors
O
Olivier Beauchet
Lead Sponsor
C
Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to explore the use of an intelligent digital health companion called "Talk-to-Jo" designed for older adults living with neurocognitive disorders (NCDs) and their caregivers. With the rising number of people over 65 expected to have NCDs by 2050, this study addresses the challenges faced by patients and their caregivers in accessing adequate support and healthcare. The study focuses on improving the quality of life for both groups through telehealth and artificial intelligence technologies. Participants will interact with the Talk-to-Jo digital avatar on a tablet, which asks questions about memory and depression and provides personalized health recommendations. The study includes a session where a research team member explains the tool, followed by the participant engaging with Talk-to-Jo, possibly assisted by their caregiver. After the interaction, a 30-minute interview is conducted to gather impressions, digital skills, barriers, and expectations regarding the AI companion. Additional interviews may be offered if needed. During the study, researchers will observe usage behaviors and collect feedback from both people with NCDs and their caregivers about enablers and barriers to using Talk-to-Jo. The study assessments last about 15 minutes for each measure. The goal is to evaluate the usability and acceptability of the technology to ensure it meets the needs of patients and caregivers. Participation involves questionnaires, interaction with the avatar, and interviews, with all activities conducted in French.
CONDITIONS
Brief Title
Talk-to-Jo" Intelligent Digital Health Companion, Neurocognitive Disorders and Dyads
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be 65 years old or older.
- Have a mild to moderate neurocognitive disorder diagnosed within the past year.
- Receive care for the neurocognitive disorder at an outpatient clinic.
- Have a caregiver who assists you.
- Live in a personal home or non-medical senior residence.
- Be able to understand spoken and written French.
You will not qualify if you...
- Unable to provide informed consent.
- Participating in another experimental clinical study.
- Living in a long-term care facility or medicalized section of a senior residence.
- Unable to understand spoken or written French.
- Having moderate to severe visual or hearing impairments that affect communication, unless using aids.
- For caregivers: having a neurocognitive disorder.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants test the Talk-to-Jo intelligent digital health companion on a tablet, followed by a 30-minute interview to gather impressions and feedback about the tool, digital skills, barriers, facilitators, and expectations.
1 visit (in-person)
Duration - As needed
An additional individual interview can be arranged if required to further understand participants' experiences and expectations.
Up to 1 additional visit (in-person)
Trial Site Locations
Total: 1 location
1
CRIUGM
Montreal, Quebec, Canada, H3W1W5
Actively Recruiting
Research Team
O
Olivier Beauchet, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here